2. Search Result
Search Result
Pathways Recommended: Metabolic Enzyme/Protease
Results for "

Metabolic stability

" in MedChemExpress (MCE) Product Catalog:

161

Inhibitors & Agonists

3

Screening Libraries

2

Biochemical Assay Reagents

7

Peptides

1

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-146486
    P2Y2R/GPR17 antagonist 1

    		P2Y Receptor Inflammation/Immunology
    P2Y2R/GPR17 antagonist 1 (Compound 14m) is a dual P2Y2R and GPR17 antagonist with IC50 values of 3.17 µM and 1.67 µM against P2Y2R and GPR17, respectively. P2Y2R/GPR17 antagonist 1 shows excellent metabolic stability in human liver microsomes .
    P2Y2R/GPR17 antagonist 1
  • HY-103053
    PS121912

    		VD/VDR Apoptosis Cancer
    PS121912 is a selective vitamin D receptor (VDR)-coregulator inhibitor. PS121912 has acceptable metabolic stability in vivo. PS121912 can be used for the research of cancer .
    PS121912
  • HY-152479
    Topoisomerase IIα-IN-7

    		Topoisomerase Cancer
    Topoisomerase IIα-IN-7 is an DNA topoisomerase IIα inhibitor with an IC50 value of 7.7 µM. Topoisomerase IIα-IN-7 has broad-spectrum cytotoxicity to leukemia, lung, colon, melanoma, ovarian, kidney, prostate and breast cancer cells. Topoisomerase IIα-IN-7 has metabolic stability .
    Topoisomerase IIα-IN-7
  • HY-169258
    PDE4-IN-21

    		Phosphodiesterase (PDE) Metabolic Disease
    PDE4-IN-21 (Compound L19) is a poetent PDE4 inhibitor, with an IC50 of 0.48 μM. PDE4-IN-21 exhibits good inhibitory activity and remarkable metabolic stability in rat liver microsomes .
    PDE4-IN-21
  • HY-101930A
    (Rac)-BMS-816336

    		11β-HSD Metabolic Disease
    (Rac)-BMS-816336 (Compound 6n) is a racemate of BMS-816336. (Rac)-BMS-816336 is a potent inhibitor of human and mouse 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme with IC50s of 10 nM and 68 nM, respectively. (Rac)-BMS-816336 has good metabolic stability .
    (Rac)-BMS-816336
  • HY-147657
    GABAA receptor modulator-2

    		GABA Receptor Neurological Disease
    GABAA receptor modulator-2 (Compound 20) is selective, orally active α5-GABAAR negative allosteric modulator (NAM) with a Ki of 4.1 nM. GABAA receptor modulator-2 shows high-metabolic stability and good CNS safety .
    GABAA receptor modulator-2
  • HY-146120
    Antitubercular agent-25

    		Bacterial Infection
    Antitubercular agent-25 (Compound 28) is an anti-tubercular agent with an extracellular IC50 of 0.42 μM and an intracellular IC50 of 0.20 μM against M. tuberculosis H37Rv. Antitubercular agent-25 exhibits good metabolic stability .
    Antitubercular agent-25
  • HY-169064
    HIV-1 inhibitor-75

    		HIV Reverse Transcriptase Infection
    HIV-1 inhibitor-75 is a human immunodeficiency virus 1 (HIV-1) inhibitor, with an EC50 value ranging from 0.0039 to 0.338 μM. The binding target of HIV-1 inhibitor-75 is reverse transcriptase, with an IC50 value of 0.055 μM. HIV-1 inhibitor-75 shows good in vitro metabolic stability, exhibiting moderate clearance rates and a longer half-life in human plasma and liver microsomes .
    HIV-1 inhibitor-75
  • HY-150578
    Keap1-Nrf2-IN-12

    		Keap1-Nrf2 Inflammation/Immunology
    Keap1-Nrf2-IN-12 is a potent Keap1-Nrf2 inhibitor with an IC50 value of 2.30 µM. Keap1-Nrf2-IN-12 shows metabolic stability in human liver microsomes .
    Keap1-Nrf2-IN-12
  • HY-137608
    Uridine 5'-O-thiodiphosphate

    UDP-β-S

    		 P2Y Receptor Cardiovascular Disease
    Uridine 5'-O-thiodiphosphate (UDP-β-S) is a stable analog of UDP. As a selective agonist of P2Y6 receptor, Uridine 5'-O-thiodiphosphate has higher metabolic stability and can be used in the study of cardiovascular diseases .
    Uridine 5'-O-thiodiphosphate
  • HY-149339
    hnNOS-IN-2

    		NO Synthase Neurological Disease
    hnNOS-IN-2 (compound 17) is a human neuronal nitric oxide synthase (hnNOS) inhibitor with good metabolic stability. hnNOS-IN-2 can be used for research in neurodegenerative diseases .
    hnNOS-IN-2
  • HY-107460
    LDN-211904 oxalate

    		Ephrin Receptor Cancer
    LDN-211904 oxalate is a potent and reversible EphB3 inhibitor with an IC50 of 79 nM. LDN-211904 oxalate shows good metabolic stability in mouse liver microsomes. LDN-211904 oxalate with Cetuximab (HY-P9905) could be effective in inhibiting STAT3-activated colorectal cancer (CRC) stemness and Cetuximab resistance in CRC .
    LDN-211904 oxalate
  • HY-115981
    NS5A-IN-2

    		HCV Protease Infection
    NS5A-IN-2 (Compound 33) is a potent inhibitor of NS5A. NS5A-IN-2 has extremely high potency against HCV genotype 1b, improved activity against genotype 3a (GT 3a) and good metabolic stability . NS5A-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    NS5A-IN-2
  • HY-162928
    RIPK1-IN-26

    		RIP kinase Neurological Disease
    RIPK1-IN-26 (Compound 8a) is a potent receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor with cell anti-necroptosis potency. RIPK1-IN-26 demonstrats good metabolic stability and good binding specificity in mice. RIPK1-IN-26 is promising for research of PET imaging probe development and neurodegenerative disorders .
    RIPK1-IN-26
  • HY-144286
    CXCR4 antagonist 3

    		CXCR Infection
    CXCR4 antagonist 3 (compound 12a) is a potent antagonist of CXCR4 with an IC50 of 11 nM. CXCR4 antagonist 3 is a congener of TIQ15. CXCR4 antagonist 3 demonstrates the best overall properties including CXCR4 antagonism, CYP 2D6 inhibition, metabolic stability, and permeability. CXCR4 antagonist 3 has the potential for the research of human immunodeficiency virus .
    CXCR4 antagonist 3
  • HY-151340
    Antitubercular agent-32

    		Bacterial Infection
    Antitubercular agent-32 is a derivate of Benzothiazinone (HY-13579A), inhibits M. tuberculosis, and shows improved metabolic stability and enhanced water solubility. Antitubercular agent-32 exerts antitubercular effect by targeting decaprenylphosphoryl-β-D-ribose 2’-oxidase (DprE1, IC50=3.9 μM) .
    Antitubercular agent-32
  • HY-163783
    CSNK2-IN-1

    		Casein Kinase Infection
    CSNK2-IN-1 is a potent and selective CSNK2 inhibitor with IC50 of 1.7 nM and 0.66 nM for CSNK2A1 and CSNK2A2, respectively. CSNK2-IN-1 has antiviral activity against beta-coronaviruses such as SARS-CoV-2 and MHV. CSNK2-IN-1 has good solubility, metabolic stability, and low cytotoxicity, but its plasma concentration in vivo decreases rapidly and is insufficient to achieve pharmacological effects. CSNK2-IN-1 can be used in the research of antiviral drug development .
    CSNK2-IN-1
  • HY-163032
    FABP4-IN-3

    		FABP Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    FABP4-IN-3 (compound C3) is a highly selective FABP4 inhibitor (FABP4 Ki = 25 ± 3 a nM, FABP3 Ki = 15.03 μM) which exhibits a 601-fold selectivity over FABP3. FABP4-IN-3 also shows metabolic stability and potent cellular anti-inflammatory activity, making it promising to get involved in the research of metabolic disease, cardiac dysfunction and inflammation-related disease .
    FABP4-IN-3
  • HY-16986
    EPZ011989
    2 Publications Verification

    		 Histone Methyltransferase Cancer
    EPZ011989 is a potent and orally active Zeste Homolog 2 (EZH2) inhibitor with metabolic stability. EPZ011989 has inhibitory inhibition for EZH2 with a Ki value of <3 nM. EPZ011989 shows robust methyl mark inhibition and anti-tumor activity. EPZ011989 can be used for the research of various cancers . EPZ011989 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    EPZ011989
  • HY-152473
    Topoisomerase IIα-IN-6

    		Topoisomerase Cancer
    Topoisomerase IIα-IN-6 (Compound 47d) is an inhibitor of DNA topoisomerase IIα/β. Topoisomerase IIα-IN-6 inhibits human topoisomerase IIα and human topoisomerase IIβ with IC50 values of 0.67 µM and 0.55 µM, respectively. Topoisomerase IIα-IN-6 has stable metabolism .
    Topoisomerase IIα-IN-6
  • HY-16986A
    EPZ011989 trifluoroacetate

    		Histone Methyltransferase Cancer
    EPZ-011989 trifluoroacetate is a potent and orally active Zeste Homolog 2 (EZH2) inhibitor with metabolic stability. EPZ-011989 trifluoroacetate has inhibitory inhibition for EZH2 with a Ki value of <3 nM. EPZ-011989 trifluoroacetate shows robust methyl mark inhibition and anti-tumor activity. EPZ-011989 trifluoroacetate can be used for the research of various cancers . EPZ011989 (trifluoroacetate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    EPZ011989 trifluoroacetate
  • HY-115982
    NS5A-IN-3

    		HCV Protease Infection
    NS5A-IN-3 (Compound 15) is a potent inhibitor of NS5A. NS5A-IN-3 has extremely high potency against HCV genotype 1b, improved activity against genotype 3a (GT 3a) and good metabolic stability. NS5A-IN-3 exhibits a higher resistance barrier than daclatasvir against genotype 1b . NS5A-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    NS5A-IN-3
  • HY-146617
    GLS1 Inhibitor-4

    		Glutaminase Apoptosis Cancer
    GLS1 Inhibitor-4 (compound 41e) is a potent GLS1 inhibitor with an IC50 of 11.86 nM. GLS1 Inhibitor-4 shows antiproliferative activity, good metabolic stability, robust GLS1 binding affinity. GLS1 Inhibitor-4 blocks the glutamine metabolism and induce the production of ROS. GLS1 Inhibitor-4 induces apoptosis and shows antitumor activity .
    GLS1 Inhibitor-4
  • HY-145852
    Top/HDAC-IN-2

    		HDAC Topoisomerase Apoptosis Cancer
    Top/HDAC-IN-2 (45b), a Top and HDAC dual inhibitor, exhibits potent antitumor activities and induces apoptosis .
    Top/HDAC-IN-2
  • HY-170894
    SARS-CoV-2 Mpro-IN-37

    		SARS-CoV Infection
    SARS-CoV-2 Mpro-IN-37 (compound 8r) is a SARS-CoV-2 main protease (M pro) inhibitor, with an IC50 of 0.0199 μM. SARS-CoV-2 Mpro-IN-37 inhibits SARS-CoV-1 M pro and MERS-CoV M pro with IC50s of 0.00945 and 0.111 μM, respectively. SARS-CoV-2 Mpro-IN-37 displays high antiviral activity in the nanomolar range without showing cellular toxicity .
    SARS-CoV-2 Mpro-IN-37
  • HY-170919
    FGFR2/3-IN-2

    		FGFR Cancer
    FGFR2/3-IN-2 (compound 10) is an orally active FGFR2 and FGFR3 inhibitor. FGFR2/3-IN-2 inhibits FGFR2 and FGFR3 with IC50s of 3.7 nM and 31.2 nM (preincubation time 1 h), respectively. FGFR2/3-IN-2 spares FGFR1/4 and other kinases without causing diarrhea and serum phosphate elevation in vivo. FGFR2/3-IN-2 induces tumor stasis or regression in the SNU-16 gastric cancer model .
    FGFR2/3-IN-2
  • HY-150684
    GXH-II-052

    		Epigenetic Reader Domain Cancer
    GXH-II-052 is a potent bivalent bromodomain and extraterminal domain (BET) inhibitor. GXH-II-052 shows binding potential for BRD4-1, BRD4-2, BRD4-T, BRDT-1, BRDT-2, BRDT-T with Kd values of 28, 9.1, 4.8, 0.6, 8.4, 2.6 nM, respectively. GXH-II-052 shows antiproliferative activity. GXH-II-052 decreases the expression of c-Myc .
    GXH-II-052
  • HY-150683
    NC-III-49-1

    		Epigenetic Reader Domain Cancer
    NC-III-49-1 is a potent bivalent bromodomain and extraterminal domain (BET) inhibitor. NC-III-49-1 shows binding potential for BRD4-1, BRD4-2, BRD4-T, BRDT-1, BRDT-2, BRDT-T with Kd values of 0.095, 0.32, 0.29, 0.089, 5.5, 0.058 nM, respectively. NC-III-49-1 shows antiproliferative activity. NC-III-49-1 decreases the expression of c-Myc .
    NC-III-49-1
  • HY-146616
    GLS1 Inhibitor-3

    		Glutaminase Cancer
    GLS1 Inhibitor-3 (compound C147) is a potent GLS1 inhibitor with an IC50 of 27.98 nM. GLS1 Inhibitor-3 shows antiproliferative activity .
    GLS1 Inhibitor-3
  • HY-120438
    TASP0415914

    		PI3K Akt Inflammation/Immunology
    TASP0415914 is a potent and orally active PI3Kγ inhibitor with an IC50 of 29 nM. TASP0415914 also shows potent Akt inhibitory activities with an IC50 of 294 nM. TASP0415914 can be used for inflammatory diseases research .
    TASP0415914
  • HY-163477
    PIP5K1C-IN-2

    		PI4P5K Cancer
    PIP5K1C-IN-2 (compound 33) is a potent and selective 4-phosphate 5-kinases 1 C (PIP5K1C) inhibitor with an IC50 value of 0.0059 µM .
    PIP5K1C-IN-2
  • HY-163751
    STING-IN-9

    		Mineralocorticoid Receptor Metabolic Disease
    STING-IN-9 (compound 2) is a potent inhibitor of human CYP11B2. STING-IN-9 showed more than 80 times higher selectivity over human CYP11B1 in vitro .
    STING-IN-9
  • HY-150719
    AIMP2-DX2-IN-1

    		Aminoacyl-tRNA Synthetase Cancer
    AIMP2-DX2-IN-1 (Compound 35) is a potent AIMP2-DX2 inhibitor with an IC50 of 0.1063 μM .
    AIMP2-DX2-IN-1
  • HY-115727
    BET-IN-1

    		Epigenetic Reader Domain Others
    BET-IN-1 is a potent BET inhibitor that has excellent brain penetration and reasonable metabolic stability.
    BET-IN-1
  • HY-155071
    MmpL3-IN-2

    		Bacterial Infection
    MmpL3-IN-2 is an MmpL3 inhibitor with low cytotoxicity and moderate metabolic stability for tuberculosis research .
    MmpL3-IN-2
  • HY-161300
    Antibacterial agent 191

    		Bacterial Antibiotic Infection
    Antibacterial agent 191 (compound 11a) is a potent semi-synthetic antibiotic. Antibacterial agent 191 exhibits preferable metabolic stability .
    Antibacterial agent 191
  • HY-163087
    PT-91

    		Orphan Receptor Neurological Disease Metabolic Disease
    PT-91 is an agonist of GPR27. PT-91 exhibits high metabolic stability and brain exposure in mice .
    PT-91
  • HY-170571
    BE2647

    		Mitochondrial Metabolism Metabolic Disease Inflammation/Immunology
    BE2647 is a selective inhibitor for mitochondrial pyruvate carrier (MPC) with an EC50 of 70 nM. BE2647 exhibits good metabolic stability in mouse liver microsomes. BE2647 can be used in research of metabolic diseases, non-alcoholic fatty liver disease (MASLD), or non-alcoholic steatohepatitis (MASH) .
    BE2647
  • HY-P10889
    CNI103

    		Phosphatase Inflammation/Immunology
    CNI103 is a highly potent and metabolically stable cell-permeable peptide inhibitor of calcineurin. CNI103 selectively blocks the interaction between calcineurin and NFATc3 (KD=16 nM), thereby preventing NFATc3 activation in vitro and in vivo. CNI103 can be used to study acute respiratory distress syndrome (ARDS) and other inflammatory diseases .
    CNI103
  • HY-148075
    PI4KIIIbeta-IN-11

    		PI4K Infection
    PI4KIIIbeta-IN-11 is an inhibitor of PI4KIIIβ, with a mean pIC50 value of at least 9.1. PI4KIIIβ plays a key role in diseases research of RNA viruses and Plasmodium falciparum .
    PI4KIIIbeta-IN-11
  • HY-170651
    CDK4/6/HDAC-IN-1

    		CDK HDAC Apoptosis Cancer
    CDK4/6/HDAC-IN-1 (Compound N14) is a dual-targeting inhibitor of CDK4/6 and HDAC (IC50: CDK4 = 7.23 nM, CDK6 = 13.20 nM, HDAC1 = 55.66 nM, HDAC6 = 48.38 nM). CDK4/6/HDAC-IN-1 induces cell Apoptosis and G0/G1 phase arrest through HDAC-p21-CDK signaling pathway. CDK4/6/HDAC-IN-1 inhibits hepatocellular carcinoma .
    CDK4/6/HDAC-IN-1
  • HY-16946
    CP-610431

    		Acetyl-CoA Carboxylase Metabolic Disease
    CP-610431 is a reversible, ATP-uncompetitive, isozyme-nonselective acetyl-CoA carboxylase (ACC) inhibitor. CP-610431 inhibits ACC1 and ACC2 with IC50s of ~50 nM. CP-610431 can be used for the research of metabolic syndrome .
    CP-610431
  • HY-163291
    AM4085

    		Bacterial Infection
    AM4085 is an orally active Antagonist for FmlH with an IC50 of 0.19 μM. AM4085 reveals metabolic stability in mouse liver microsomes and blood plasma .
    AM4085
  • HY-P5984
    Thioether-cyclized helix B peptide, CHBP

    		mTOR Others
    Thioether-cyclized helix B peptide, CHBP can improve metabolic stability and renoprotective effect through inducing autophagy via inhibition of mTORC1 and activation of mTORC2 .
    Thioether-cyclized helix B peptide, CHBP
  • HY-105955
    FPL 14294

    ARL 14294

    		 Cholecystokinin Receptor Metabolic Disease
    FPL 14294 is a intranasally active anorectic agent and a cholecystokinin octapeptide (CCK) analog with enhanced metabolic stability. FPL 14294 induces satiety in many species and can be utilized in relevant research .
    FPL 14294
  • HY-170942
    CDK9/PARP-IN-1

    		CDK PARP Cancer
    CDK9/PARP-IN-1 (compound 37) is a CDK9/PARP inhibitor. CDK9/PARP-IN-1 inhibits CDK9 and PARP1 with IC50s of 118 and 107 nM, respectively. CDK9/PARP-IN-1 exhibits broad-spectrum antiproliferative effects across multiple cancer cell lines .
    CDK9/PARP-IN-1
  • HY-116001
    (+)-Carbovir

    NSC 614846

    		 HIV Endogenous Metabolite Infection
    (+)-Carbovir (NSC 614846) is an antiviral drug with activity against human immunodeficiency virus type 1. (+)-Carbovir is a nucleoside analog with enhanced chemical and metabolic stability. (+)-Carbovir can be used in AIDS research .
    (+)-Carbovir
  • HY-168297
    Piperidine-C2-Pip-C-COOH

    		PROTAC Linkers Cancer
    Piperidine-C2-Pip-C-COOH is a linker for PROTAC BTK Degrader-5 (HY-155072), significantly improving metabolic stability, and can be used in cancer research .
    Piperidine-C2-Pip-C-COOH
  • HY-172423
    Darlifarnib

    		Farnesyl Transferase Cancer
    Darlifarnib (Compound (S)-058) is the inhibitor for farnesyl transferase and geranylgeranyltransferase with IC50 ≤ 10 nM and ＞ 1000 nM. Darlifarnib exhibits good metabolic stability in human and mouse liver microsomes with the half-life time ＞ 100 min .
    Darlifarnib
  • HY-161993
    BI-9787

    		Ketohexokinase Metabolic Disease
    BI-9787 is a zwitterionic inhibitior for ketohexokinase, with an IC50 of 12 and 12.8 nM for hKHK-A and hKHK-C. BI-9787 exhibits good metabolic stability in rat hepatocyte and good pharmacokinetic characteristics in rats .
    BI-9787

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: